COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension (QUALITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00795262
Recruitment Status : Completed
First Posted : November 21, 2008
Last Update Posted : May 5, 2011
Information provided by:
InVasc Therapeutics, Inc.

Brief Summary:
We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.

Condition or disease Intervention/treatment Phase
Diabetes Hypertension Drug: Quinapril (Accupril) plus Alpha Lipoic Acid Drug: accupril, placebo Drug: accupril, alpha lipoic acid Not Applicable

Detailed Description:
The participant will be randomized to either quinapril 40 mg and alpha lipoic acid versus quinapril 40 mg and placebo for 8 weeks. There will be a wash out period of 4 weeks between the cross over. The participant will be assigned the cross over for 8 weeks on the opposite therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 22-week Randomized, Cross-over Study Comparing the Effects of Quinapril and Quinapril Plus Alpha-lipoic Acid (ALA) on Patients With Diabetes Mellitus and Hypertension
Study Start Date : July 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Arm Intervention/treatment
Placebo Comparator: placebo comparator
Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
Drug: accupril, placebo
accupril 40 mg
Other Names:
  • Accupril
  • quinapril

Active Comparator: Active comparator
Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
Drug: Quinapril (Accupril) plus Alpha Lipoic Acid
Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
Other Names:
  • ALA
  • Alpha Lipoic Acid
  • Quinapril
  • Accupril

Drug: accupril, alpha lipoic acid
accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
Other Names:
  • quinapril
  • accupril
  • ALA
  • alpha lipoic acid
  • lipoic acid

Primary Outcome Measures :
  1. Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo. [ Time Frame: The total study period is 22 weeks i.e. the initial prescreening visit followed 1 week later by the baseline study visit, 8 weeks of treatment (Treatment A or B), 4 weeks washout, 8 weeks of treatment (Treatment A or B). ]

Secondary Outcome Measures :
  1. Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin [ Time Frame: at baseline (week-1), weeks 8, 12 and 20. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients who have a diagnosis of diabetes mellitus as defined by fasting blood glucose levels greater than ot equal to 126mg/dL and a systolic BP greater than 125 mm Hg at the time of screening will be included in the study. Patients may be on antihypertensive medication but not on ACE inhibitor or ARB therapy at the time of enrollment.

Exclusion Criteria:

Systolic blood pressure > 180 mmHg Creatinine > 2.5 mg/dl Glycosylated hemoglobin > 7.5% Congestive heart failure (NYHA Class II, III or IV) Coronary angiography planned prior to baseline sampling Chronic autoimmune disease Chronic inflammatory disease or known cancer in evolution life expectancy < 1 year Immunosuppressives or treatment with any other investigational drug within the last 30 days Pregnant or nursing women Participants who experience any side effects to quinapril and/or alpha lipoic acid

Women of childbearing potential Women of childbearing potential enrolled in the study should use one of the acceptable methods of birth control as listed below

  1. Abstinence, meaning a total lack of any sexual activity.
  2. Oral contraceptives (the "pill"),
  3. Contraceptive injections,
  4. Intrauterine device,
  5. Double-barrier method (diaphragm or condom + spermicidal cream),
  6. Contraceptive patch, or
  7. Male partner sterilization.

Pregnancy Any pregnancy that occurs during study participation must be reported to the Principal Investigator and the study coordinator at the earliest. The pregnancy must be followed up to determine outcome and status of the mother and child. To ensure subject safety, any subject that becomes pregnant during the study will be discontinued from the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00795262

Layout table for location information
United States, Georgia
Atlanta Vascular Research Foundation
Tucker, Georgia, United States, 30084
Sponsors and Collaborators
InVasc Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Syed T. Rahman, MD Atlanta Vascular Research Foundation
Layout table for additonal information
Responsible Party: Syed T. Rahman, MD, Atlanta Vascular Research Foundation Identifier: NCT00795262    
Other Study ID Numbers: INV-064 QUALITY
First Posted: November 21, 2008    Key Record Dates
Last Update Posted: May 5, 2011
Last Verified: May 2011
Keywords provided by InVasc Therapeutics, Inc.:
brachial artery reactivity
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Thioctic Acid
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antihypertensive Agents